Novel Immunoassay Predicts Risk of Breast Cancer Metastasis
By LabMedica International staff writers Posted on 16 Jun 2014 |
Image: Metastasis requires the presence of three cells in direct contact on a blood vessel wall: a tumor cell that produces the protein MENA; a perivascular macrophage (cells that guide tumor cells to blood vessels); and a blood-vessel endothelial cell. The presence of three such cells in contact with each other is called a tumor microenvironment of metastasis, or TMEM, which is depicted within the box in this illustration (Photo courtesy of Albert Einstein College of Medicine of Yeshiva University).
A novel diagnostic test that identifies sites where breast tumors are able to metastasize was used to predict risk of distant metastasis in ER+/HER2− breast cancer independently of IHC4 score and classical pathologic features.
Primary breast cancers are able to metastasize when three types of cells are present together in the same site: an endothelial cell, a perivascular macrophage, and a tumor cell that produces high levels of Mena, a protein that enhances a cancer cell’s ability to spread. Tumor cells can enter blood vessels at sites where these three cells are in contact. Such a site is referred to as a tumor microenvironment of metastasis, or TMEM.
Investigators at the Albert Einstein College of Medicine (New York, NY, USA) recently developed a test that uses a triple immunostain, which contains antibodies to the three cell types that make up a TMEM. They used this test to evaluate breast tumor specimens from 259 women who later developed a distant metastasis (the cases) and on specimens from women who were alive and had not developed a distant metastasis (the controls). Case patients and control subjects were matched (1:1) on age at and calendar year of primary diagnosis. Results for the TMEM assay were compared to those obtained by the IHC4 method.
IHC4 measures the levels of four key proteins (ER, PR, HER2 and Ki-67) in addition to classical clinical and pathological variables (for example, age, nodal status, tumor size, and grade) and calculates a risk score for distant recurrence using an algorithm. Quantitative assessments of ER, PR, and Ki-67 are needed for the IHC4 test. The test uses formalin-fixed paraffin-embedded samples.
Results showed that TMEM score was significantly associated with increased risk of distant metastasis in estrogen receptor (ER)+/human epidermal growth factor receptor (HER2)− tumors, whereas IHC4 score had only a borderline positive association. Furthermore, the association for TMEM score persisted after adjustment for the IHC4 score. The area under the curve for TMEM, adjusted for clinical variables, was 0.78. Neither TMEM score nor IHC4 score was independently associated with metastatic risk overall or in the triple negative or HER2+ breast tumor subgroups.
“Currently marketed tests assess risk for breast cancer metastasis by looking for changes in gene expression or in levels of proteins associated with growth of tumor cells,” said senior author Dr. Joan Jones, professor of pathology, anatomy, and epidemiology at the Albert Einstein College of Medicine. “But those changes do not reflect the mechanism by which individual tumor cells invade blood vessels, a necessary step for metastasis. By contrast, our test is based on what Einstein researchers learned from intravital imaging, which reveals biological processes deep within the tissues of a living animal. Using this technology, they determined how breast cancer tumor cells spread in rodents.”
The study was published in the August 8, 2014, online edition of the Journal of the National Cancer Institute.
Related Links:
Albert Einstein College of Medicine
Primary breast cancers are able to metastasize when three types of cells are present together in the same site: an endothelial cell, a perivascular macrophage, and a tumor cell that produces high levels of Mena, a protein that enhances a cancer cell’s ability to spread. Tumor cells can enter blood vessels at sites where these three cells are in contact. Such a site is referred to as a tumor microenvironment of metastasis, or TMEM.
Investigators at the Albert Einstein College of Medicine (New York, NY, USA) recently developed a test that uses a triple immunostain, which contains antibodies to the three cell types that make up a TMEM. They used this test to evaluate breast tumor specimens from 259 women who later developed a distant metastasis (the cases) and on specimens from women who were alive and had not developed a distant metastasis (the controls). Case patients and control subjects were matched (1:1) on age at and calendar year of primary diagnosis. Results for the TMEM assay were compared to those obtained by the IHC4 method.
IHC4 measures the levels of four key proteins (ER, PR, HER2 and Ki-67) in addition to classical clinical and pathological variables (for example, age, nodal status, tumor size, and grade) and calculates a risk score for distant recurrence using an algorithm. Quantitative assessments of ER, PR, and Ki-67 are needed for the IHC4 test. The test uses formalin-fixed paraffin-embedded samples.
Results showed that TMEM score was significantly associated with increased risk of distant metastasis in estrogen receptor (ER)+/human epidermal growth factor receptor (HER2)− tumors, whereas IHC4 score had only a borderline positive association. Furthermore, the association for TMEM score persisted after adjustment for the IHC4 score. The area under the curve for TMEM, adjusted for clinical variables, was 0.78. Neither TMEM score nor IHC4 score was independently associated with metastatic risk overall or in the triple negative or HER2+ breast tumor subgroups.
“Currently marketed tests assess risk for breast cancer metastasis by looking for changes in gene expression or in levels of proteins associated with growth of tumor cells,” said senior author Dr. Joan Jones, professor of pathology, anatomy, and epidemiology at the Albert Einstein College of Medicine. “But those changes do not reflect the mechanism by which individual tumor cells invade blood vessels, a necessary step for metastasis. By contrast, our test is based on what Einstein researchers learned from intravital imaging, which reveals biological processes deep within the tissues of a living animal. Using this technology, they determined how breast cancer tumor cells spread in rodents.”
The study was published in the August 8, 2014, online edition of the Journal of the National Cancer Institute.
Related Links:
Albert Einstein College of Medicine
Latest Pathology News
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes
- Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases